INmune Bio Inc (INMB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, INmune Bio Inc (INMB) has a cash flow conversion efficiency ratio of -0.214x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.44 Million) by net assets ($25.38 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
INmune Bio Inc - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how INmune Bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read INMB liabilities breakdown for a breakdown of total debt and financial obligations.
INmune Bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of INmune Bio Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Werewolf Therapeutics Inc
NASDAQ:HOWL
|
-0.512x |
|
RedCloud Holdings plc Ordinary Shares
NASDAQ:RCT
|
1.989x |
|
US Energy Corp
NASDAQ:USEG
|
-0.006x |
|
WPP PLC
LSE:WPP
|
-0.304x |
|
Culp, Inc. Common Stock
NYSE:CULP
|
-0.022x |
|
Display Tech Co. Ltd
KQ:066670
|
0.068x |
|
Dabomb Protein
TWO:6578
|
-0.013x |
|
TNR Gold Corp.
V:TNR
|
-1.253x |
Annual Cash Flow Conversion Efficiency for INmune Bio Inc (2015–2024)
The table below shows the annual cash flow conversion efficiency of INmune Bio Inc from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see INMB market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $32.10 Million | $-33.36 Million | -1.039x | -230.89% |
| 2023-12-31 | $38.14 Million | $-11.98 Million | -0.314x | +16.78% |
| 2022-12-31 | $60.10 Million | $-22.69 Million | -0.377x | -6.23% |
| 2021-12-31 | $80.22 Million | $-28.50 Million | -0.355x | -53.96% |
| 2020-12-31 | $38.75 Million | $-8.94 Million | -0.231x | -1.19% |
| 2019-12-31 | $23.61 Million | $-5.38 Million | -0.228x | -83.20% |
| 2018-12-31 | $16.54 Million | $-2.06 Million | -0.124x | -195.83% |
| 2017-12-31 | $18.10 Million | $-761.83K | -0.042x | -101.98% |
| 2016-12-31 | $-149.20K | $-317.38K | 2.127x | +121.52% |
| 2015-12-31 | $-18.87K | $-18.12K | 0.960x | -- |
About INmune Bio Inc
INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of pati… Read more